Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of “Buy” from Analysts

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have received an average rating of “Buy” from the seven analysts that are covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $23.00.

A number of brokerages have issued reports on AURA. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. BTIG Research increased their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a research report on Thursday, November 14th. Finally, Scotiabank upped their target price on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th.

Insider Activity at Aura Biosciences

In related news, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the transaction, the insider now directly owns 151,693 shares of the company’s stock, valued at $1,419,846.48. The trade was a 7.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the sale, the insider now directly owns 304,692 shares in the company, valued at approximately $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,778 shares of company stock valued at $240,706 in the last quarter. Insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aura Biosciences during the fourth quarter worth about $87,000. American Century Companies Inc. purchased a new stake in shares of Aura Biosciences in the second quarter worth approximately $119,000. SG Americas Securities LLC bought a new position in shares of Aura Biosciences in the third quarter valued at approximately $169,000. JPMorgan Chase & Co. lifted its holdings in shares of Aura Biosciences by 107.5% in the third quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company’s stock valued at $477,000 after purchasing an additional 27,718 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after buying an additional 43,897 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Trading Up 0.1 %

Shares of AURA stock opened at $7.93 on Friday. The stock has a market cap of $396.10 million, a P/E ratio of -4.58 and a beta of 0.30. Aura Biosciences has a 1 year low of $6.63 and a 1 year high of $12.38. The stock has a 50 day simple moving average of $8.30 and a 200 day simple moving average of $8.91.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. Analysts forecast that Aura Biosciences will post -1.67 EPS for the current year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.